Pioneers in

Motivated to
change lives

PYC Therapeutics is a drug-development company offering a new generation of RNA therapeutics to meet unmet need in disease.

We have world-leading RNA targeted therapeutics design capabilities which are supported by our revolutionary delivery technology based on Cell Penetrating Peptides (CPPs) to overcome the ‘delivery challenge’ in genomic therapies.

Our differentiated drug delivery capability and RNA drug design experts means we have the skills and means to discover and develop RNA-targeted therapeutics in a truly innovative way. We have three defined preclinical programs for Inherited Retinal Diseases, and a strong focus on Central Nervous System diseases.

Guided by world-class scientists and business leaders who are at the forefront of innovation in their fields, our team has significant experience in the biotechnology sector.

Pioneers in RNA therapeutics, combined with a proprietary delivery technology

Our life-changing science is based on combining our platform technologies: Our proprietry Cell-Penetrating Peptide technology and our PMO-design technology (PPMOs).

Our dedicated team of international scientists are guided by our Chief Scientific Officer, Professor Sue Fletcher, a pioneer in RNA therapies who co-invented Exondys-51, Vyondys-53 and Casimerson (commercialized by Sarepta).

We are harnessing a new generation of RNA-targeted therapeutics called PPMOs to develop precise and highly effective treatments for disease.

Our people

Executive Leadership Board of Directors Scientific Advisory Board Ophthalmology Clinical Advisory Board

Stay Connected.